

Horizon Europe

THE NEXT EU RESEARCH & INNOVATION
INVESTMENT PROGRAMME (2021 – 2027)

#HorizonEU

Irene Norstedt, acting Director
Research & Innovation DG, People Directorate

SGPP meeting
Brussels, 23 January 2020



Towards the launch of Horizon Europe



Towards the launch of Horizon Europe

– cascade of pending decision-making in 2020



Horizon Europe: Preliminary structure (€ 94.1 bn)



Pillar 1 - € 25.8bn
Excellent Science

European Research Council

Marie Skłodowska-Curie
Actions

Research Infrastructures



Pillar 2 - € 52.7 bn
Global Challenges and
European Industrial
Competitiveness

Clusters

- **Health – € 7.7 bn**
- Culture, Creativity and Inclusive Society
- Civil Security for Society
- Digital, Industry and Space
- Climate, Energy and Mobility
- Food, Bioeconomy, Natural Resources, Agriculture and Environment

Joint Research Centre



Pillar 3 - € 13.5 bn
Innovative Europe

European Innovation Council

European innovation
ecosystems

European Institute of
Innovation
and Technology

Widening Participation and Strengthening the European Research Area – € 2.1 bn

Widening participation and spreading excellence

Reforming and Enhancing the European R&I system

Commission proposal for synergies with other Union programmes

Horizon Europe



Other Union Programmes, including

Common Agricultural Policy
ERDF
External Instrument
Maritime & Fisheries Fund
InvestEU

LIFE
Connecting Europe Facility
ESF+
Digital Europe
Space Programme

Erasmus
Innovation Fund
Internal Security Fund
Single Market Programme



Enhanced synergies

Compatibility

Harmonisation of funding rules; flexible co-funding schemes; pooling resources at EU level

Coherence and complementarity

Alignment of strategic priorities in support of a common vision

Orientations towards the first Strategic Plan 2021-2024

Targeted Impacts of the Health Cluster

- 1. Staying healthy in a rapidly changing society;**
- 2. Living and working in a health-promoting environment;**
- 3. Tackling diseases and reducing disease burden;**
- 4. Ensuring access to innovative, sustainable and high-quality healthcare**
- 5. Unlocking the full potential of new tools, technologies and digital solutions for a healthy society**
- 6. Maintaining an innovative, sustainable and globally competitive health industry**

Health Cluster Partnership Candidates

Institutional Partnerships (Article 185 and Article 187 TFEU)

2021 - Innovative Health Initiative (ex-IMI2)

2021 - EU-Africa Global Health (ex-EDCTP2)

Co-funded Partnerships

2021 - Partnership on Assessment of Risk of Chemicals (PARC)

2022 - Personalised Medicine

2023 - Rare Diseases

2023 - Large-scale innovation and transformation of health systems in a digital and ageing society

2024 - One Health AMR

2024 - Fostering an ERA for Health research

Partnerships with Member States

kind of support and commitments needed

Article 185/187 initiatives with Member State participation:

→ National commitments (typically from national ministries) before COM proposal is adopted

Co-funded European Partnership with Member States:

→ Indicative national commitments (typically from national ministries) at the moment of including the topic for the Programme-co-fund action supporting the Partnerships in the draft Annual Work Programme Horizon Europe

→ Confirmation of commitments with the submission of the proposal

Co-programmed European Partnership with Member States:

→ National commitments (typically from national ministries) at the moment of concluding the “Contractual arrangements /MoUs” and adopting Annual Work Programme Horizon Europe

Innovative Health Initiative (IMI2 successor)

- Accelerate the **development of safer and more effective innovative healthcare interventions** that respond to **unmet public health needs**, and that **can be taken up** by healthcare systems

BY

- European collaborative platform for precompetitive and integrative R&I **facilitating technology integration** to:
 - ↳ advance science and contribute to the **development of innovative health solutions**
 - ↳ strengthen **competitiveness** of Europe's health tech industry
 - ↳ incentivize industry to **invest in unmet public health needs**
 - ↳ shorten the **time-to-market** of innovative products and services
 - ↳ Contribute to **improved health outcomes** and to the **sustainability of the healthcare systems**.

THROUGH

- An **institutionalised** European Partnership (Art 187) as of **2021** between the **EU** and the **European health-related industries** for pharmaceuticals, diagnostics, medical devices, imaging, biotech and digital health

EU-Africa Global Health Partnership

(EDCTP2 successor)

- To **reduce social and economic burden of infectious diseases** in sub-Saharan Africa and in Europe (e.g. tuberculosis and HIV/AIDS in Eastern Europe), thereby contributing to SDG3

AND

- To **increase health security in sub-Saharan Africa and Europe**, in particular in the context of climate change

BY

- **accelerating the development** of effective, safe, accessible, suitable and affordable **health technologies**
- **improving health systems interventions** for infectious diseases
- considering co-morbidities and antimicrobial resistance

THROUGH

- An **institutionalised or co-funded** European Partnership as of **2021** between **EU member states, sub-Saharan African countries** and the **EU**

Process for the preparation, adoption and launch of Art. 185/187 initiatives



Summer
2019

- Early involvement and exchanges with Member States
- Open public consultation on **Inception Impact Assessment**
- Start of the study supporting **Impact Assessment (IA)**

Autumn-
winter
2019/2020

- Open public consultation on the 12 institutionalized partnerships (Sept-Nov)
- Final report of studies supporting IA submitted in December
- Submission of IA drafts to Regulatory Scrutiny Board (submission mid-February, hearing mid-March 2020)

2020

- Adoption of Commission proposals (Q1/2020)
- Negotiation with and adoption by Council, and where relevant European Parliament (until end of 2020)

2021

- Launch of the initiatives (as of early 2021)

European Partnership for Chemicals Risk Assessment (HBM4EU successor)

- To **strengthen European capacities** in the areas of: human biomonitoring; environmental and food monitoring; toxicology and hazard assessments; exposure assessment; emerging chemicals; chemical mixtures; validation, standardisation and reference materials; risk assessment methodologies; data management and analysis; communication, dissemination and training; priority setting and sustainability.

BY

- supporting established **chemical regulatory processes** and facilitate their **adaptation to and preparedness for persistent or emerging challenges**
- providing **new evidence and methodologies** and stimulate their uptake in regulatory processes.

THROUGH

- A **co-funded** European Partnership as of **2021** between **EU and national chemical risk assessment and management authorities**

European Partnership on Personalised Medicine

- increase of **healthcare care systems efficiency** through innovation and a **patient-centred approach** in the provision of healthcare, including via digital solutions

BY

- **aligning priority setting and funding** for research projects in the area of personalised medicine:
 - integrating big data and digital health solutions
 - translating basic research into clinical applications
 - providing socio-economic evidence for the uptake of PM by the health systems

THROUGH

- A **co-funded** European Partnership as of **2022** between **EU Member States and regions, associated countries** and **international partner countries**

European Partnership on Rare Diseases

- To **improve lives of rare diseases patients**, in particular to improve health outcomes of rare diseases patients resulting in increased life expectancy, capacity to work and sustainability of health and care systems

BY

- developing the ecosystem for discovery research and development of new diagnostic tools and therapies for rare diseases providing an efficient and **effective "pipeline" from research to healthcare**
- delivering **better prevention strategies, diagnostic tools and treatment options** for these diseases
- Advancing the **capacity to collect and share all relevant data at EU and international level** and efficiently utilizing data collected by the European Reference Networks

THROUGH

- A **co-funded** European Partnership as of **2023** between **EU Member States and other stakeholders**

Large-scale innovation and transformation of health systems in a digital and ageing society

A European Partnership on Health and Care Systems R&I

- To support **large-scale innovation and transformation of health systems** in a digital and ageing society

BY

- boosting research in policy, uptake and scale-up of innovations to accelerate transformation of national/regional health and care systems, incl.
 - Provide science-based evidence for health and care systems innovations;
 - Develop science-based frameworks for monitoring and evaluating innovative solutions;
 - Build knowledge on the conditions for transferability and up-scaling;
 - Define and prioritise unmet needs of citizens and health and care systems;
 - Establish an R&I platform that brings together health and health research data across health and care systems to enable data-driven policy in accordance with the GDPR.

THROUGH

- An **co-funded** European Partnership as of **2023** with **funders of research and innovation**, including R&I funding agencies, health system owners and healthcare payers

European Partnership on 'One Health AMR'

- To contribute achieving the objectives of the **European One Health Action Plan against AMR** and the **WHO Global Action Plan on AMR**, and overcome fragmentation between/within countries and policy sectors

BY

- improving **national, EU and global coordination** of research investments and activities as well as **collaboration** between international research initiatives
 - Developing novel solutions to prevent/treat infections affected by AMR
 - Closing knowledge gaps on AMR (including those identified in the European One Health Action Plan against AMR and the EU Strategic Approach to Pharmaceuticals in the Environment), supporting regulatory science, informing evidence-based policy-making

THROUGH

- A **co-funded** European Partnership as of **2024** between **EU Member States and other stakeholders**

European Partnership fostering a European Research Area in Health research

- To co-design and jointly implement **common funding strategies in priority areas** to advance health research and develop innovation and applications in health and care

BY

- **coordinating** health research **investments**
- **networking** clinical research **capacities** and research **infrastructures**,
- establishing modalities of **data sharing** and **use of health data** for new digital health technologies and tools and for people-centred care

THROUGH

- A **co-funded** European Partnership as of **2024** between **public funders of health research in the European Research Area**

Conclusions

- List of health cluster partnership candidates have been discussed and agreed with the (shadow) Programme Committee of Horizon Europe
- Discussions with potential partners have been launched, incl. with representatives of Member States
 - Have SGPP members already been involved in discussions at national level as regards any of these Health cluster partnership candidates?
- EC proposals for the two institutionalised partnerships are in preparation and will be finalized soon
 - Have SGPP any advice on the scope of the two candidates for institutionalised partnerships, i.e. the EU-Africa Global Health Partnership and the Innovative Health Initiative?